

# CURRICULUM VITAE

## BIOGRAPHICAL

Name: SUNG-HOON JUNG

Birth Date: December 21, 1978

Birth Place: Gwangju, Korea

Citizenship: Republic of Korea

Home address: 310-6, Banpo-daero, Seocho-gu, Seoul, Korea

Business Address: 160 Ilshimri, Hwasuneup, Jellanamdo,  
Republic of Korea

E-mail Address: shglory@hanmail.net

Business Phone: 82-61-379-7659

Business Fax: 82-61-379-7628

## Education and Training

List entries in each section chronologically

### UNDERGRADUATE:

<i>Dates Attended</i>	<i>Name and Location of Institution</i>	<i>Degree Received and Year</i>	<i>Major subject</i>
March 1, 1997	Chonnam National University Medical School, Gwangju, Korea	Bachelor Feb. 24, 2003	Medicine

### GRADUATE:

<i>Dates Attended</i>	<i>Name and Location of Institution</i>	<i>Degree Received and Year</i>	<i>Major advisor and Discipline</i>
March 1, 2004	Chonnam National University, Gwangju, Korea	Master Feb. 24, 2006	Je-Jung Lee Medical science
March 3, 2013	Chonam National University Gwangju, Korea	Ph.D Aug, 26,2015	Je-Jung Lee

### POSTGRADUATE

Include internship, residencies, fellowships and/or any other professional training experience

<i>Dates Attended</i>	<i>Name and Location of Institution</i>	<i>Name of Program Director and Discipline</i>
2003.3 - 2004. 2	Chonnam National University Hospital, Gwangju, Korea	Tai-Ju Hwang Internship
2004. 3 - 2008. 2	Chonnam National University Hospital, Gwangju, Korea	Ki-Chul Choi Residency in Department of Internal Medicine

2011. 5 - 2012.05	Chonnam National University Hospital, Gwangju, Korea	Je-Jung Lee Fellowship in Department of Hematology-Oncology
2012.06 -2016.10	Chonnam National University Hospital, Gwangju, Korea	Clinical Assistant Professor in Department of Hematology-Oncology
2016.11-2017.08	Chonnam National University Hospital, Gwangju, Korea	Clinical Associate Professor in Department of Hematology-Oncology
2017.09-2020.10.	Chonnam National University Hospital Gwangju, Korea	Associate Professor in Department of Hematology-Oncology
2020.12~2021.02	Ewha Woman's University Seoul Hospital Seoul, Korea	Clinical Associate professor in Department of Hematology-Oncology
2021.03~	Chonnam National University Hwasun Hospital Hwasun, Korea	Clinical Associate professor in Department of Hematology-Oncology

## PUBLICATIONS

1. **Jung SH**, Kwon SY, Min JJ, Bom HS, Ahn SY, Jung SY, Lee SS, Park MR, Yang DH, Ahn JS, Kim HJ, Lee JJ. <sup>18</sup>F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. *Eur J Nucl Med Mol Imaging*. 2019 Jan;46(1):107-115. doi: 10.1007/s00259-018-4114-0.
2. Vo MC, Lakshmi TJ, **Jung SH**, Cho D, Park HS, Chu TH, Lee HJ, Kim HJ, Kim SK, Lee JJ. Cellular immunotherapy in multiple myeloma. *Korean J Intern Med*. 2019 Feb 15. doi: 10.3904/kjim.2018.325.
3. **Jung SH**, Lee SR, Yang DH, Lee S, Yoon JH, Lee H, Bang SM, Koh Y, Park S, Kim DS, Yhim HY, Kim SH, Lee JH, Sohn SK, Song IC, Lee HG, Cheong JW, Choi Y, Shin HJ. Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party. *Ann Hematol*. 2019 Jan;98(1):151-158. doi: 10.1007/s00277-018-3495-2
4. Song GY, **Jung SH**, Ahn SY, Jung SY, Yang DH, Ahn JS, Kim HJ, Lee JJ. Optimal chemomobilization for the collection of peripheral blood stem cells in patients with multiple myeloma. *BMC Cancer*. 2019 Jan 14;19(1):59. doi: 10.1186/s12885-019-5285-1.
5. Vo MC, Yang S, **Jung SH**, Chu TH, Lee HJ, Lakshmi TJ, Park HS, Kim HJ, Lee JJ. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model. *Front Immunol*. 2018 Aug 3;9:1798. doi: 10.3389/fimmu.2018.01798. eCollection 2018.
6. Lee YJ, Baek DW, Ahn JS, Ahn SY, **Jung SH**, Yang DH, Lee JJ, Kim HJ, Ham JY, Suh JS, Sohn SK, Moon JH. Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. *Clin Lymphoma Myeloma Leuk*. 2018 Dec;18(12):e529-e535. doi: 10.1016/j.clml.2018.08.010.

7. Kim T, Moon JH, Ahn JS, Kim YK, Lee SS, Ahn SY, **Jung SH**, Yang DH, Lee JJ, Choi SH, Lee JY, Tyndel MS, Shin MG, Lee YJ, Sohn SK, Park SK, Zhang Z, Kim HJ, Kim DDH. Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. *Blood*. 2018 Oct 11;132(15):1604-1613. doi: 10.1182/blood-2018-04-848028.
8. Kim T, Choi HY, Lee HS, **Jung SH**, Ahn JS, Kim HJ, Lee JJ, Yoo HD, Yang DH. Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL). *BMC Cancer*. 2018 Jul 9;18(1):729. doi: 10.1186/s12885-018-4632-y.
9. Vo MC, **Jung SH**, Chu TH, Lee HJ, Lakshmi TJ, Park HS, Kim HJ, Rhee JH, Lee JJ. Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma. *Front Immunol*. 2018 Jun 18;9:1370. doi: 10.3389/fimmu.2018.01370. eCollection 2018.
10. Ahn SY, Kwon SY, **Jung SH**, Ahn JS, Yoo SW, Min JJ, Bom HS, Ki SY, Kim HJ, Lee JJ, Song SY, Yang DH. Prognostic Significance of Interim 11C-Methionine PET/CT in Primary Central Nervous System Lymphoma. *Clin Nucl Med*. 2018 Aug;43(8):e259-e264. doi: 10.1097/RLU.0000000000002154.
11. **Jung SH**, Lee JJ, Kim JS, Min CK, Kim K, Choi Y, Eom HS, Joo YD, Kim SH, Kwak JY, Kang HJ, Lee JH, Lee HS, Mun YC, Moon JH, Sohn SK, Park SK, Park Y, Shin HJ, Yoon SS; Korean Multiple Myeloma Working Party. Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). *Biol Blood Marrow Transplant*. 2018 May;24(5):923-929. doi: 10.1016/j.bbmt.2018.01.004
12. **Jung SH**, Ahn SY, Choi HW, Shin MG, Lee SS, Yang DH, Ahn JS, Kim YK, Kim HJ, Lee JJ. STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma. *Blood Res*. 2017 Dec;52(4):293-299. doi: 10.5045/br.2017.52.4.293.
13. **Jung SH**, Lee JJ, Kim K, Suh C, Yoon DH, Min CK, Sohn SK, Choi CW, Lee HS, Kim HJ, Shin HJ, Bang SM, Yoon SS, Park SK, Yhim HY, Kim MK, Jo JC, Mun YC, Lee JH, Kim JS; Korean Multiple Myeloma Working Party. The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). *Oncotarget*. 2017 Jun 16;8(45):79517-79526. doi: 10.18632/oncotarget.18535.
14. Vo MC, Nguyen-Pham TN, Lee HJ, **Jung SH**, Choi NR, Hoang MD, Kim HJ, Lee JJ. Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells. *Oncotarget*. 2017 Jul 11;8(28):46047-46056. doi: 10.18632/oncotarget.17517.
15. **Jung SH**, Kim K, Kim JS, Kim SJ, Cheong JW, Kim SJ, Ahn JS, Ahn SY, Yang DH, Kim HJ, Lee JJ. A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System. *Br J Haematol*. 2018 Jun;181(5):707-710. doi: 10.1111/bjh.14701.
16. Vo MC, Nguyen-Pham TN, Lee HJ, Jaya Lakshmi T, Yang S, **Jung SH**, Kim HJ, Lee JJ. Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance

- antitumor immunity in a mouse colon cancer model. *Oncotarget*. 2017 Apr 18;8(16):27252-27262. doi: 10.18632/oncotarget.15917.
17. **Jung SH**, Lee HJ, Vo MC, Kim HJ, Lee JJ. Immunotherapy for the treatment of multiple myeloma. *Crit Rev Oncol Hematol*. 2017 Mar;111:87-93. doi: 10.1016/j.critrevonc.2017.01.011.
  18. **Jung SH**, Lee HJ, Lee YK, Yang DH, Kim HJ, Rhee JH, Emmrich F, Lee JJ. A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma. *Oncotarget*. 2017 Jun 20;8(25):41538-41548. doi: 10.18632/oncotarget.14582.
  19. Kim T, Tyndel MS, Kim HJ, Ahn JS, Choi SH, Park HJ, Kim YK, Yang DH, Lee JJ, **Jung SH**, Kim SY, Min YH, Cheong JW, Sohn SK, Moon JH, Choi M, Lee M, Zhang Z, Kim DDH. The clonal origins of leukemic progression of myelodysplasia. *Leukemia*. 2017 Sep;31(9):1928-1935. doi: 10.1038/leu.2017.17.
  20. Byun JM, Koh Y, Shin DY, Kim I, Yoon SS, Lee JO, Bang SM, Kim KH, **Jung SH**, Lee WS, Park Y, Jang JH, Han JJ, Yhim HY, Kim DS, Lee YJ, Lee H, Choi YS, Lee S; Korean Adult ALL Working Party, Korean Society of Hematology. *BCR-ABL* translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors. *Haematologica*. 2017 May;102(5):e187-e190. doi: 10.3324/haematol.2016.159988.
  21. Ahn JS, Kim HJ, Kim YK, Lee SS, Ahn SY, **Jung SH**, Yang DH, Lee JJ, Park HJ, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Michael S, Minden MD, Kim DD. 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia. *Oncotarget*. 2017 Jan 31;8(5):8305-8314. doi: 10.18632/oncotarget.14171.
  22. Vo MC, Anh-NguyenThi T, Lee HJ, Nguyen-Pham TN, Jaya Lakshmi T, **Jung SH**, Kim HJ, Lee JJ. Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma. *Exp Hematol*. 2017 Feb;46:48-55. doi: 10.1016/j.exphem.2016.11.004.
  23. Hong CY, Lee HJ, Choi NR, **Jung SH**, Vo MC, Hoang MD, Kim HJ, Lee JJ. Sarcoplasmic reticulum Ca(2+) ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells. *Exp Mol Med*. 2016 Aug 19;48(8):e253. doi: 10.1038/emmm.2016.69.
  24. **Jung SH**, Cho MS, Kim HK, Kim SJ, Kim K, Cheong JW, Kim SJ, Kim JS, Ahn JS, Kim YK, Yang DH, Kim HJ, Lee JJ; Korean Multiple Myeloma Working Party (KMMWP). Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. *BMC Cancer*. 2016 Aug 8;16:613. doi: 10.1186/s12885-016-2645-y.
  25. **Jung SH**, Choi HJ, Shin MG, Lee SS, Hwang EC, Jung TY, Cho MS, Yang DH, Ahn JS, Kim YK, Kim HJ, Lee JJ. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression. *Ann Hematol*. 2016 Oct;95(10):1645-51. doi: 10.1007/s00277-016-2743-6.
  26. **Jung SH**, Kim JS, Lee WS, Oh SJ, Ahn JS, Yang DH, Kim YK, Kim HJ, Lee JJ. Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen. *Ann Hematol*. 2016 Jan;95(1):55-61

27. Ahn JS, Kim HJ, Kim YK, Lee SS, **Jung SH**, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2016 Jan;22(1):61-70. doi: 10.1016/j.bbmt.2015.07.030.
28. Nguyen HH, Kim T, Song SY, Park S, Cho HH, **Jung SH**, Ahn JS, Kim HJ, Lee JJ, Kim HO, Cho JH, Yang DH. Naïve CD8(+) T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF- $\beta$  immunosuppression in the tumor microenvironment. *Sci Rep*. 2016 Jun 16;6:28208. doi: 10.1038/srep28208.
29. Ahn JS, Kim HJ, Kim YK, **Jung SH**, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. *Ann Hematol*. 2016 Mar;95(4):625-35. doi: 10.1007/s00277-015-2580-z.
30. Ahn JS, Kim JY, Kim HJ, Kim YK, Lee SS, **Jung SH**, Yang DH, Lee JJ, Kim NY, Choi SH, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. *Ann Hematol*. 2016 Jan;95(2):301-10. doi: 10.1007/s00277-015-2540-7.
31. Kim T, Yoshida K, Kim YK, Tyndel MS, Park HJ, Choi SH, Ahn JS, **Jung SH**, Yang DH, Lee JJ, Kim HJ, Kong G, Ogawa S, Zhang Z, Kim HJ, Kim DD. Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression. *Leukemia*. 2016 Feb;30(2):295-302. doi: 10.1038/leu.2015.264.
32. **Jung SH**, Lee JJ, Kim WS, Lee WS, Do YR, Oh SY, Kim MK, Mun YC, Shin HJ, Kwak JY, Kang HJ, Won JH, Kwon JH, Park E, Suh C, Yang DH. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL). *Eur J Haematol*. 2015 Jun;94(6):504-10. doi: 10.1111/ejh.12459.
33. **Jung SH**, Yang DH, Ahn JS, Kim YK, Kim HJ, Lee JJ. Serum lactate dehydrogenase with systemic inflammation score is a useful indicator to predict response and survival in patients with newly diagnosed diffuse large B-cell lymphoma. *Acta Haematol*. 2015;133(1):10-7. doi: 10.1159/000360068.
34. **Jung SH**, Ahn JS, Kim YK, Kweon SS, Min JJ, Bom HS, Kim HJ, Chae YS, Moon JH, Sohn SK, Lee SW, Byun BH, Do YR, Lee JJ, Yang DH. Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. *BMC Cancer*. 2015 Mar 28;15:198. doi: 10.1186/s12885-015-1193-1
35. Nguyen-Pham TN, **Jung SH**, Vo MC, Thanh-Tran HT, Lee YK, Lee HJ, Choi NR, Hoang MD, Kim HJ, Lee JJ. Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma. *J Immunother*. 2015 Oct;38(8):330-9. doi: 10.1097/CJI.0000000000000097.
36. **Jung SH**, Ahn JS, Yang DH, Cho MS, Kim JY, Ahn SY, Kim YK, Kim HJ, Lee JJ. Oliguria as an

early indicator of mortality risk in patients with multiple myeloma and renal impairment. *Blood Res.* 2015 Sep;50(3):167-72. doi: 10.5045/br.2015.50.3.167.

37. Ahn JS, Yang DH, **Jung SH**, Lee JJ, Kim I, Park S, Chung JS, Shin HJ, Kim DY, Lee KH, Moon JH, Sohn SK, Song IC, Jo DY, Joo YD; Korean Society of Hematology Adult ALL Working Party. Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party. *Acta Haematol.* 2015;133(1):91-7. doi: 10.1159/000362261.
38. Lee SS, Ahn JS, **Jung SH**, Ahn SY, Kim JY, Jang HC, Kang SJ, Jang MO, Yang DH, Kim YK, Lee JJ, Kim HJ. Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation. *Korean J Intern Med.* 2015 Mar;30(2):212-8. doi: 10.3904/kjim.2015.30.2.212.
39. Ahn JS, Kim HJ, Kim YK, **Jung SH**, Yang DH, Lee JJ, Lee IK, Kim NY, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim N, Yoshida K, Ogawa S, Kim DD. Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype. *Haematologica.* 2015 Sep;100(9):e351-3. doi: 10.3324/haematol.2015.126227.
40. Choi NR, Lee HJ, **Jung SH**, Hong CY, Vo MC, Hoang MD, Kim HJ, Lee JJ. Generation of potent dendritic cells with improved migration ability through p-cofilin and sarco/endoplasmic reticulum Ca(2+) transport ATPase 2 regulation. *Cytotherapy.* 2015 Oct;17(10):1421-33. doi: 10.1016/j.jcyt.2015.06.002.
41. Hoang MD, Lee HJ, Lee HJ, **Jung SH**, Choi NR, Vo MC, Nguyen-Pham TN, Kim HJ, Park IK, Lee JJ. Branched Polyethylenimine-Superparamagnetic Iron Oxide Nanoparticles (bPEI-SPIONs) Improve the Immunogenicity of Tumor Antigens and Enhance Th1 Polarization of Dendritic Cells. *J Immunol Res.* 2015;2015:706379. doi: 10.1155/2015/706379.
42. **Jung SH**, Kang SJ, Jang HC, Ahn JS, Yang DH, Lee SS, Kim YK, Kim HJ, Lee JJ. Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens. *Int J Hematol.* 2014 Nov;100(5):473-7. doi: 10.1007/s12185-014-1672-1.
43. **Jung SH**, Jang HC, Lee SS, Ahn JS, Yang DH, Kim YK, Kim HJ, Lee JJ. The impact of hyperglycemia on risk of severe infections during early period of induction therapy in patients with newly diagnosed multiple myeloma. *Biomed Res Int.* 2014;2014:413149. doi: 10.1155/2014/413149.
44. Ahn SY, **Jung SH**, Joo YD, Lee WS, Lee SM, Choi CW, Kim SJ, Kim K, Lee JJ; Korean Multiple Myeloma Working Party. Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study. *Ann Hematol.* 2014 Sep;93(9):1571-7. doi: 10.1007/s00277-014-2067-3.
45. Ahn JS, **Jung SH**, Lee SS, Ahn SY, Yang DH, Kim YK, Kim HJ, Lee JJ. Clinical outcome of bortezomib retreatment in patients with relapsed or refractory multiple myeloma. *Biomed Res Int.* 2014;2014:145843. doi: 10.1155/2014/145843
46. **Jung SH**, Yang DH, Ahn JS, Kim YK, Kim HJ, Lee JJ. Advanced lytic lesion is a poor mobilization

- factor in peripheral blood stem cell collection in patients with multiple myeloma. *J Clin Apher.* 2014 Dec;29(6):305-10. doi: 10.1002/jca.21326.
47. **Jung SH**, Lee YK, Lee HJ, Choi NR, Vo MC, Hoang MD, Lim MS, Nguyen-Pham TN, Kim HJ, Lee JJ. Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro. *Exp Hematol.* 2014 Apr;42(4):274-81. doi: 10.1016/j.exphem.2013.12.008.
  48. **Jung SH**, Yang DH, Ahn JS, Lee SS, Ahn SY, Kim YK, Kim HJ, Lee JJ. Decreased body mass index is associated with poor prognosis in patients with multiple myeloma. *Ann Hematol.* 2014 May;93(5):835-40. doi: 10.1007/s00277-013-1977-9.
  49. Ahn JS, **Jung SH**, Yang DH, Bae SY, Kim YK, Kim HJ, Lee JJ. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma. *Clin Lymphoma Myeloma Leuk.* 2014 Oct;14(5):389-94. doi: 10.1016/j.clml.2014.02.004.
  50. **Jung SH**, Bae SY, Ahn JS, Kang SJ, Yang DH, Kim YK, Kim HJ, Lee JJ. Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens. *Int J Hematol.* 2013 Mar;97(3):382-7. doi: 10.1007/s12185-013-1270-7.
  51. **Jung SH**, Park H, Ahn JS, Yang DH, Kim MY, Kim YK, Kim HJ, Lee JJ. Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen. *Int J Hematol.* 2013 Jan;97(1):92-7. doi: 10.1007/s12185-012-1237-0.
  52. Ahn JS, Yang DH, **Jung SH**, Chae YS, Sohn SK, Yhim HY, Kwak JY, Lee SR, Kim YK, Kim HJ, Lee JJ. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial. *Ann Hematol.* 2013 Jun;92(6):789-97. doi: 10.1007/s00277-013-1685-5.
  53. Ahn JS, Rew SY, Yang DH, **Jung SH**, Kang SJ, Kim MY, Lee SS, Kim YK, Kim HJ, Lee JJ. Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma. *Blood Res.* 2013 Mar;48(1):35-9. doi: 10.5045/br.2013.48.1.35.
  54. Ahn JS, Yang DH, Duk Choi Y, **Jung SH**, Yhim HY, Kwak JY, Sung Park H, Shin MG, Kim YK, Kim HJ, Lee JJ. Clinical outcome of elderly patients with Epstein-Barr virus positive diffuse large B-cell lymphoma treated with a combination of rituximab and CHOP chemotherapy. *Am J Hematol.* 2013 Sep;88(9):774-9. doi: 10.1002/ajh.23507.